Valuation: Supernus Pharmaceuticals, Inc.

Market Cap 2.73B 2.4B 2.23B 2.05B 3.85B 261B 3.9B 26.52B 10.36B 129B 10.24B 10.02B 446B P/E 2026 *
106x
P/E 2027 * 31.4x
Enterprise Value 2.73B 2.4B 2.23B 2.05B 3.85B 261B 3.9B 26.52B 10.36B 129B 10.24B 10.02B 446B EV / Sales 2026 *
3.14x
EV / Sales 2027 * 2.67x
Free-Float
95.54%
Yield 2026 *
-
Yield 2027 * -
1 day+1.69%
1 week-0.93%
Current month+1.01%
1 month+0.30%
3 months-5.01%
6 months-4.98%
Current year-5.47%
1 week 45.84
Extreme 45.8425
48.12
1 month 45.8
Extreme 45.8
51.37
Current year 42.45
Extreme 42.45
59.68
1 year 32.83
Extreme 32.83
59.68
3 years 21.99
Extreme 21.99
59.68
5 years 21.99
Extreme 21.99
59.68
10 years 13.12
Extreme 13.12
61.25
Manager TitleAgeSince
Chief Executive Officer 64 21/12/2005
Director of Finance/CFO 67 22/08/2021
Compliance Officer 63 31/12/2011
Director TitleAgeSince
Director/Board Member 64 21/12/2005
Chairman 81 09/08/2016
Director/Board Member 80 15/11/2010
Date Insider Type Main position Quantity % Market Cap.
16/03/26 Fiscal year

Chief Technology Officer

321,750 0.5738%
13/03/26 Others

Founder

60,000 0.1070%
12/03/26 Sell

Director

5,369 0.0096%
Change 5-day change 1-year change 3-year change Capi.($)
+1.69%-0.93%+39.90%+55.92% 2.73B
-0.24%+5.11%+54.36%+24.21% 323B
+1.87%+5.04%+25.89%-11.68% 70.11B
-0.55%+5.69%+39.90%+87.27% 9.66B
-0.04%+0.06%+3.30%-1.24% 8.51B
+1.61%+6.64%-20.18%-2.50% 4.37B
-3.87%+4.05%-41.18%+10.04% 3.66B
+3.53%+4.14%-2.33%+15.23% 3.75B
+3.60%-2.63%-4.72%-8.34% 2.11B
+1.63%-0.45%-14.93%+27.83% 1.87B
Average +0.73%+1.65%+8.00%+19.67% 42.97B
Weighted average by Cap. -0.15%+3.11%+45.63%+18.86%

Financials

2026 *2027 *
Net sales 867M 762M 710M 652M 1.22B 83.16B 1.24B 8.44B 3.29B 41.06B 3.26B 3.19B 142B 1.02B 899M 837M 769M 1.44B 98.09B 1.46B 9.95B 3.89B 48.44B 3.84B 3.76B 167B
Net income 25.92M 22.79M 21.21M 19.48M 36.58M 2.49B 37.07M 252M 98.49M 1.23B 97.32M 95.22M 4.24B 92.99M 81.75M 76.1M 69.89M 131M 8.92B 133M 905M 353M 4.4B 349M 342M 15.22B
Net Debt - -
Logo Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a range of CNS product candidates including new potential treatments for epilepsy, depression, ADHD, and other CNS disorders. Its products marketed in the United States include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC, ONAPGOTM (formerly known as SPN-830), and ZURZUVAE. Qelbree (viloxazine extended-release capsules) is a non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.
Employees
778
Date Price Change Volume
27/07/26 US$46.98 +1.69% 523,013
24/07/26 US$46.20 -2.10% 521,935
23/07/26 US$47.19 +0.53% 463,337
22/07/26 US$46.94 -1.94% 430,060
21/07/26 US$47.87 +0.95% 450,290
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
46.98USD
Average target price
63.50USD
Spread / Average Target
+35.16%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SUPN Stock